Select Bibliography

Filter by any of these (after searching):

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 12 items

Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance)

Ailawadhi, Sikander , McCarthy, Philip L. , Holstein, Sarah A. ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Meta-Analysis - Transplant - CALGB-100104 , E4A03 , MM-002 , MM-009

Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-Institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002)

Bashey, Asad , Owzar, Kouros , Johnson, Jeffrey L. ... - - Biol. Blood Marrow Transplant. - 2011

Manuscript - Primary - Primary - Transplant - CALGB-100002

A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502

Devine, S. M. , Owzar, K. , Blum, W. , Deangelo, D. , Stone, R. M. ... - ASH - ASH Annual Meeting Abstracts - 2012

Abstract - Primary - Primary - Transplant - CALGB-100103

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502

Devine, Steven M. , Owzar, Kouros , Blum, William , Mulkey, Flora ... - - J. Clin. Oncol - 2015

Manuscript - Primary - Primary - Transplant - CALGB-100103

A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study

Farag, S. , Owzar, K. , Hars, V. , Lazarus, H. M. , Stadtmauer, E. A. ... - ASH - Blood - 2009

Abstract - Primary - Primary - Transplant - CALGB-100101

Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): Initial report of patient accrual and adverse events

Mccarthy, P. L. , Linker, C. , Hofmeister, C. C. , Owzar, K. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Primary - Preliminary - Transplant - CALGB-100104

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Mccarthy, P. L. , Owzar, K. , Anderson, K. C. , Hofmeister, C. C. ... - ASH - Blood - 2010

Abstract - Primary - Primary - Transplant - CALGB-100104

Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (Pts) with advanced indolent NHL and CLL: CALGB 109901

Shea, T. C. , Johnston, J. , Walsh, W. , Farag, S. , Mccarty, J. ... - - Blood - 2007

Abstract - Primary - Primary - Transplant - CALGB-109901

Reduced Intensity Allogeneic Transplantation Provides High Event-Free And Overall Survival In Patients With Advanced Indolent B Cell Malignancies: CALGB 109901

Shea, Thomas , Johnson, Jeffrey , Westervelt, Peter , Farag, Sherif ... - - Biol Blood Marrow Transplant - 2011

Manuscript - Primary - Primary - Transplant - CALGB-109901

CALGB 100801 (Alliance): A phase II multi-center study of the addition of azacitidine (AZA) following allogeneic transplantation using a targeted busulfan based conditioning regimen for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML)

Vij, Ravi , Hars, Vera , Blum, William , Shore, Tsiporah ... - EBMT - Bone Marrow Transplantation - 2015

Abstract - Primary - Primary - Transplant - CALGB-100801

CALGB 100801 (Alliance): A phase II multi-center NCI cooperative group study of the addition of azacitidine (AZA) to reduced-intensity conditioning (RIC) allogeneic transplantation for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML): Results of a busulfan test dose strategy

Vij, Ravi , Hars, Vera , Shea, Thomas , Hoke, Eva , Blum, William ... - ASH - Blood - 2014

Abstract - Secondary - Primary - Transplant - CALGB-100801

A phase II multi-center study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplantation for high-risk myelodysplasia (and older patients with acute myeloid leukemia: CALGB 100801 (Alliance)

Vij, Ravi , Le-Rademacher, Jennifer , Laumann, Kristina , Hars, Vera ... - - Biol. Blood Marrow Transplant. - 2019

Manuscript - Primary - Primary - Transplant - CALGB-100801